Myung A. Lee

Seoul St
Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Monocyte-plasma cell communication characterizes treatment-associated peripheral immune remodeling in Guillain-Barré syndrome.

Monocyte-plasma cell communication characterizes treatment-associated peripheral immune remodeling in Guillain-Barré syndrome.

Journal: Frontiers in immunology

Published: July 08, 2026

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 21, 2026

A phase II study of alpelisib and capecitabine in patients with previously treated metastatic colorectal cancer (KCSG-CO21-04).

A phase II study of alpelisib and capecitabine in patients with previously treated metastatic colorectal cancer (KCSG-CO21-04).

Journal: Scientific reports

Published: December 19, 2025

Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumors.

Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumors.

Journal: JCI insight

Published: December 17, 2025

Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19).

Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19).

Journal: Cancer research and treatment

Published: November 18, 2025

Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer's disease: a nationwide real-world study.

Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer's disease: a nationwide real-world study.

Journal: Alzheimer's research & therapy

Published: November 09, 2025

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized controlled trial.

Journal: BMC cancer

Published: October 11, 2025

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin.

Journal: JCO precision oncology

Published: October 02, 2025

Dynamic Integrative Immune Profiling Reveals Early Biomarkers of Response and Prognosis in Advanced Gastric Cancer Treated with Nivolumab Plus Chemotherapy.

Dynamic Integrative Immune Profiling Reveals Early Biomarkers of Response and Prognosis in Advanced Gastric Cancer Treated with Nivolumab Plus Chemotherapy.

Journal: Cancers

Published: August 16, 2025

The Hospice and Palliative Medicine Physicians Certification Programs across Countries/Regions.

The Hospice and Palliative Medicine Physicians Certification Programs across Countries/Regions.

Journal: Journal of hospice and palliative care

Published: April 10, 2025

Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.

Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer.

Journal: Journal of hepatology

Published: March 17, 2025

Skeletal Muscle Density as a Predictor of Prognosis and Physical Reserve in Patients with Cancer of Unknown Primary.

Skeletal Muscle Density as a Predictor of Prognosis and Physical Reserve in Patients with Cancer of Unknown Primary.

Journal: Journal of clinical medicine

Published: March 14, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026